Abstract 87P
Background
Liver metastases were observed in more than 25% of colon cancer patients when initially diagnosed. We aim to perform a retrospective analysis to investigate the pathological characteristics and treatment experience of synchronous liver metastasis (CLM) using data from the Population-based Surveillance, Epidemiology, and End Results (SEER) database. Furthermore, we intend to identify potential prognostic factors and build origin predictive models for evaluating 3-year and 5-year cancer-specific survival (CSS) and overall survival (OS) of CLM.
Methods
CLM patients were collected from SEER database between 2010 and 2015. Univariate and multivariate cox regression analyses were conducted to identify the potential predictors of patient’s survival outcomes. The selected variables were integrated to create predictive nomograms via R tools. Furthermore, the concordance index Harrell’s C statistic (C-index) was calculated to describe the discrimination of nomograms. Calibration (1000 bootstrap resamples) curves were plotted to compare predictions of the nomogram and observed outcomes. Subsequently, Decision Curve Analysis (DCA) and clinical impact curves were performed to evaluate the clinical effects of nomograms.
Results
Total 11,812 CLM patients were included after eliminating those with missing information. Tumor primary site, tumor size, histological grade, T /N stage, surgery of other regions, bone/lung metastasis, CEA level, tumor deposits, regional positive nodes, and chemotherapy were used to construct the predictive models of CSS and OS of CLM. Final nomograms indicated relatively good discrimination (C-index = 0.74 for OS and C-index = 0.73 for CSS). The calibration curves of CSS and OS suggested a good agreement. In addition, DCAs and clinical impact curves reflected favorable potential clinical effects. Online webserver of our nomograms was established for convenient utilization (https://predictivetools.shinyapps.io/CSSDynNomapp/;https://predictivetools.shinyapps.io/OS-DynNomapp/).
Conclusions
The nomograms were built on the webserver and validated to effectively and timely predict the CSS and OS of colon cancer patients with synchronous liver metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session